JP5337493B2 - セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 - Google Patents

セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 Download PDF

Info

Publication number
JP5337493B2
JP5337493B2 JP2008558710A JP2008558710A JP5337493B2 JP 5337493 B2 JP5337493 B2 JP 5337493B2 JP 2008558710 A JP2008558710 A JP 2008558710A JP 2008558710 A JP2008558710 A JP 2008558710A JP 5337493 B2 JP5337493 B2 JP 5337493B2
Authority
JP
Japan
Prior art keywords
phe
cys
glu
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2008558710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529553A5 (enExample
JP2009529553A (ja
Inventor
ピエール ベリシャール，
Original Assignee
ダイアックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダイアックス コーポレーション filed Critical ダイアックス コーポレーション
Publication of JP2009529553A publication Critical patent/JP2009529553A/ja
Publication of JP2009529553A5 publication Critical patent/JP2009529553A5/ja
Application granted granted Critical
Publication of JP5337493B2 publication Critical patent/JP5337493B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2008558710A 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法 Active JP5337493B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP06360008.4 2006-03-16
EP06360008 2006-03-16
EP06291516 2006-09-26
EP06291516.0 2006-09-26
PCT/EP2007/002216 WO2007104541A2 (en) 2006-03-16 2007-03-13 Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012171140A Division JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2009529553A JP2009529553A (ja) 2009-08-20
JP2009529553A5 JP2009529553A5 (enExample) 2011-03-10
JP5337493B2 true JP5337493B2 (ja) 2013-11-06

Family

ID=38292592

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558710A Active JP5337493B2 (ja) 2006-03-16 2007-03-13 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012171140A Withdrawn JP2012211194A (ja) 2006-03-16 2012-08-01 セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法

Country Status (12)

Country Link
US (3) US20070270344A1 (enExample)
JP (2) JP5337493B2 (enExample)
AU (1) AU2007224643B2 (enExample)
CA (1) CA2646285C (enExample)
DK (1) DK1854477T3 (enExample)
ES (2) ES2601554T3 (enExample)
HU (2) HUE031701T2 (enExample)
LT (2) LT2374472T (enExample)
PL (1) PL1854477T3 (enExample)
PT (2) PT2374472T (enExample)
SI (1) SI2374472T1 (enExample)
WO (1) WO2007104541A2 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) * 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7745587B2 (en) 2005-12-30 2010-06-29 Dyax Corp. Antibodies that bind MMP-14
DK1854477T3 (en) * 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
WO2008091692A2 (en) * 2007-01-25 2008-07-31 Joslin Diabetes Center, Inc. Methods of diagnosing, treating, and preventing increased vascular permeability
CA2707637A1 (en) 2007-12-17 2009-06-25 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins
WO2010048432A1 (en) * 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
GB2510407A (en) 2013-02-04 2014-08-06 Kalvista Pharmaceuticals Ltd Aqueous suspensions of kallikrein inhibitors for parenteral administration
JP2016513682A (ja) 2013-03-15 2016-05-16 ダイアックス コーポレーション 抗血漿カリクレイン抗体
WO2015063465A2 (en) 2013-10-28 2015-05-07 Bicycle Therapeutics Limited Novel polypeptides
ES3065185T3 (en) 2014-01-21 2026-05-04 Takeda Pharmaceuticals Co Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
IL247942B (en) * 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
EP3376939B1 (en) * 2015-11-18 2022-05-11 University Of Louisville Research Foundation, Inc. Automated methods for the objective quantification of retinal characteristics by retinal region and diagnosis of retinal pathology
RU2622031C1 (ru) * 2015-12-07 2017-06-08 Государственное бюджетное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия" Министерства здравоохранения РФ Способ комбинированного лечения макулярного отека сетчатки
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
GB201522441D0 (en) * 2015-12-18 2016-02-03 Midatech Pharma Wales Ltd Sustained release cyclosporine-loaded microparticles
ES3072908T3 (en) 2019-04-08 2026-07-06 Biocryst Pharm Inc Plasma kallikrein inhibitors and methods of use thereof in ocular disorders
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
WO2021198534A1 (en) 2020-04-04 2021-10-07 Oxurion NV Plasma kallikrein inhibitors for use in the treatment of coronaviral disease
LT6899B (lt) * 2020-08-27 2022-04-11 Valstybinis mokslinių tyrimų institutas Fizinių ir technologijos mokslų centras Vario paviršiaus cheminio nikeliavimo būdas, nenaudojant aktyvavimo paladžiu
WO2023144030A1 (en) 2022-01-31 2023-08-03 Oxurion NV Plasma kallikrein inhibitor therapy for anti-vegf sensitization
WO2023148016A1 (en) 2022-02-04 2023-08-10 Oxurion NV Biomarker for plasma kallikrein inhibitor therapy response

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444156A (en) * 1985-07-12 1995-08-22 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human plasma prekallikrein
US5217951A (en) * 1986-12-24 1993-06-08 John Lezdey Treatment of inflammation
EP0737207B1 (en) * 1994-01-11 2004-09-22 Dyax Corporation Inhibitors of human plasmin derived from the kunitz domains
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
CA2180950C (en) * 1994-01-11 2005-03-29 William Markland Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
US6174859B1 (en) * 1999-04-06 2001-01-16 J & D Sciences, Inc. Method of treatment
DE10060653A1 (de) * 2000-12-06 2002-06-20 Epcos Ag Elektrischer Doppelschicht-Kondensator
US20060122374A1 (en) 2002-02-07 2006-06-08 Peter Mertins Albumin-fused anti-angiogenesis peptides
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
PT2298278E (pt) * 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
WO2004019968A1 (en) 2002-08-28 2004-03-11 Dyax Corp. Methods for preserving organs and tissues
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CA3050564A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006091459A2 (en) 2005-02-24 2006-08-31 Joslin Diabetes Center, Inc. Compositions and methods for treating vascular permeability
US7276480B1 (en) * 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US20070213275A1 (en) * 2006-03-10 2007-09-13 Dyax Corp. Formulations for ecallantide
DK1854477T3 (en) 2006-03-16 2016-11-28 Dyax Corp Peptide inhibitors of plasma kallikrein for use in the treatment of eye disorders
US8467792B2 (en) * 2006-06-27 2013-06-18 Qualcomm Incorporated Method and apparatus for maintaining call continuity in wireless communication
WO2009026334A2 (en) 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2009026539A1 (en) 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
WO2010048432A1 (en) 2008-10-22 2010-04-29 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders

Also Published As

Publication number Publication date
ES2601554T3 (es) 2017-02-15
PL1854477T3 (pl) 2017-02-28
SI2374472T1 (sl) 2018-11-30
HUE039108T2 (hu) 2018-12-28
LT2374472T (lt) 2018-09-25
WO2007104541A2 (en) 2007-09-20
ES2682646T3 (es) 2018-09-21
JP2009529553A (ja) 2009-08-20
US9107928B2 (en) 2015-08-18
HUE031701T2 (en) 2017-07-28
CA2646285C (en) 2020-04-28
US20150368359A1 (en) 2015-12-24
AU2007224643A1 (en) 2007-09-20
US20100273721A1 (en) 2010-10-28
JP2012211194A (ja) 2012-11-01
CA2646285A1 (en) 2007-09-20
PT2374472T (pt) 2018-08-08
WO2007104541A3 (en) 2008-06-26
LT1854477T (lt) 2016-12-12
PT1854477T (pt) 2016-11-10
AU2007224643B2 (en) 2012-10-11
DK1854477T3 (en) 2016-11-28
US20070270344A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
JP2009529553A (ja) セリンプロテアーゼを阻害するペプチドを用いて眼科障害を治療する組成物及び方法
Kim et al. The effect of topical bevacizumab on corneal neovascularization
US20070196350A1 (en) Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment
Morales et al. Intraoperative mitomycin and corneal endothelium after photorefractive keratectomy
Moisseiev et al. Drug delivery to the posterior segment of the eye
JP2008500282A (ja) 眼症状の治療
RU2286157C2 (ru) Средства для введения в стекловидное тело для лечения или предотвращения заболеваний глаз
JP2007523911A (ja) 眼病変治療用テトラサイクリン誘導体
Fischer et al. Drug delivery to the posterior segment of the eye
EP1854477B9 (en) Peptides inhibiting plasma kallikrein for use in the treatment of ophthalmic disorders.
Ianchulev Suprachoroidal space as a therapeutic target
CN100431544C (zh) 用于治疗病理性眼血管生成的糖皮质激素制剂
HK1162940A (en) Compositions and methods for treating ophthalmic disorders
HK1162940B (en) Compositions and methods for treating ophthalmic disorders
JP2007500250A5 (enExample)
KR20060019579A (ko) 병적 눈 혈관형성을 치료하기 위한 비-스테로이드성항-염증제 제제
AU2024366119A1 (en) Compositions and methods for treating neural degeneration in glaucoma and related conditions
WO2023144030A1 (en) Plasma kallikrein inhibitor therapy for anti-vegf sensitization
Abdelmassih et al. Complications of Newer Surgeries
AU2005232693A1 (en) Treatment of ophthalmic conditions with mineralcorticoids

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120502

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120801

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130711

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130805

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5337493

Country of ref document: JP

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250